Spark Investment Management LLC cut its position in Endologix, Inc. (NASDAQ:ELGX) by 83.7% during the first quarter, Holdings Channel reports. The fund owned 30,773 shares of the medical instruments supplier’s stock after selling 157,727 shares during the period. Spark Investment Management LLC’s holdings in Endologix were worth $203,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. Citigroup Inc. boosted its stake in Endologix by 279.2% during the fourth quarter. Citigroup Inc. now owns 51,448 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 37,882 shares during the last quarter. Macquarie Group Ltd. acquired a new position in shares of Endologix in the 4th quarter valued at $46,000. Assenagon Asset Management S.A. acquired a new position in shares of Endologix in the 4th quarter valued at $55,000. Jane Street Group LLC lifted its stake in shares of Endologix by 54.6% in the 4th quarter. Jane Street Group LLC now owns 93,572 shares of the medical instruments supplier’s stock valued at $67,000 after purchasing an additional 33,044 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. lifted its stake in shares of Endologix by 408.0% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 99,731 shares of the medical instruments supplier’s stock valued at $71,000 after purchasing an additional 80,100 shares during the last quarter.
Shares of NASDAQ ELGX opened at $6.66 on Friday. The company has a current ratio of 1.58, a quick ratio of 0.90 and a debt-to-equity ratio of 11.12. Endologix, Inc. has a 1-year low of $5.20 and a 1-year high of $67.20. The stock has a market cap of $111.80 million, a price-to-earnings ratio of -0.93 and a beta of 0.58.
Endologix (NASDAQ:ELGX) last issued its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported ($1.12) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.56) by $0.44. Endologix had a negative return on equity of 173.52% and a negative net margin of 54.72%. The company had revenue of $35.61 million for the quarter, compared to the consensus estimate of $34.18 million. On average, research analysts expect that Endologix, Inc. will post -3.98 earnings per share for the current fiscal year.
In related news, CFO Vaseem Mahboob purchased 15,128 shares of the business’s stock in a transaction on Wednesday, April 3rd. The shares were bought at an average price of $6.61 per share, for a total transaction of $99,996.08. Following the acquisition, the chief financial officer now directly owns 76,820 shares in the company, valued at $507,780.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John Onopchenko purchased 30,257 shares of the business’s stock in a transaction on Wednesday, April 3rd. The shares were bought at an average price of $6.61 per share, for a total transaction of $199,998.77. Following the acquisition, the chief executive officer now owns 96,360 shares in the company, valued at $636,939.60. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 48,410 shares of company stock worth $319,990. 1.40% of the stock is owned by company insiders.
Several brokerages have recently commented on ELGX. Zacks Investment Research raised Endologix from a “hold” rating to a “buy” rating and set a $6.75 price target on the stock in a research note on Tuesday, April 16th. ValuEngine lowered Endologix from a “buy” rating to a “hold” rating in a research note on Monday, April 1st. Stifel Nicolaus set a $7.00 price target on Endologix and gave the company a “hold” rating in a research note on Monday, April 1st. Finally, BTIG Research reaffirmed a “buy” rating on shares of Endologix in a research note on Tuesday, February 26th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. Endologix has an average rating of “Hold” and an average price target of $25.63.
TRADEMARK VIOLATION WARNING: “Endologix, Inc. (ELGX) Shares Sold by Spark Investment Management LLC” was published by Zolmax and is the sole property of of Zolmax. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://zolmax.com/investing/endologix-inc-elgx-shares-sold-by-spark-investment-management-llc/3095038.html.
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.
Recommended Story: Why are gap-down stocks important?
Want to see what other hedge funds are holding ELGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endologix, Inc. (NASDAQ:ELGX).
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.